Background:  The current prospective, randomized, controlled REVERSE-FLOW trial aims to systematically examine the effect of the glycoprotein (GP) IIb/IIIa inhibitors on infarct size in patients with STEMI and NSTEMI and angiographic evidence of no-reflow. Trial Registration No: SNCTP000003611  Trial Status: active Enrolling Centers:  5 Core Study Team: 
© Christian Mueller, 2012 - 2020 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: Mai 2020
Kristin Shrestha Home News Team Studies Publications Events Cooperations Contact Dr. Gregor Fahrni Dr. Philip Haaf